Outlook Therapeutics to Cut 23% of Workforce in Push for Lytenava Commercial Launch

Dow Jones

2024/12/14

By Sabela Ojea

Outlook Therapeutics said it would trim its workforce by 23% with the goal of extending its cash runway as long as possible and move forward with the commercial launch of Lytenava in the European Union and the U.K.

The biopharmaceutical company on Friday said that the layoffs follow an internal strategic review and would lead to annual savings of about $1.4 million. The company had cash and cash equivalents of $32 million as of June 30, down from $47.2 million as of March 31.

Lytenava is the subject of a centralized Marketing Authorization granted by the European Commission in the European Union and Marketing Authorization granted by the Medicines and Healthcare products Regulatory Agency in the U.K. for the treatment of wet age-related macular degeneration.

Wet AMD happens when abnormal blood vessels grow in the back of the eye and damage the macula.

The company continues to believe in the potential of Lytenava and is dedicated to advancing its regulatory and commercial efforts, Interim Chief Executive Lawrence Kenyon said.

Write to Sabela Ojea at sabela.ojea@wsj.com

(END) Dow Jones Newswires

December 13, 2024 16:54 ET (21:54 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2491158649"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2491158649\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2491158649?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-14 05:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2491158649","market":"hk","top_or_hot":-1,"title":"Outlook Therapeutics to Cut 23% of Workforce in Push for Lytenava Commercial Launch","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sabela Ojea \n</p>\n<pre>\n \n</pre>\n<p>\n  Outlook <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> said it would trim its workforce by 23% with the goal of extending its cash runway as long as possible and move forward with the commercial launch of Lytenava in the European Union and the U.K. \n</p>\n<p>\n  The biopharmaceutical company on Friday said that the layoffs follow an internal strategic review and would lead to annual savings of about $1.4 million. The company had cash and cash equivalents of $32 million as of June 30, down from $47.2 million as of March 31. \n</p>\n<p>\n  Lytenava is the subject of a centralized Marketing Authorization granted by the European Commission in the European Union and Marketing Authorization granted by the Medicines and Healthcare products Regulatory Agency in the U.K. for the treatment of wet age-related macular degeneration. \n</p>\n<p>\n  Wet AMD happens when abnormal blood vessels grow in the back of the eye and damage the macula. \n</p>\n<p>\n  The company continues to believe in the potential of Lytenava and is dedicated to advancing its regulatory and commercial efforts, Interim Chief Executive Lawrence Kenyon said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sabela Ojea at sabela.ojea@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 13, 2024 16:54 ET (21:54 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Outlook Therapeutics to Cut 23% of Workforce in Push for Lytenava Commercial Launch</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOutlook Therapeutics to Cut 23% of Workforce in Push for Lytenava Commercial Launch\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2024-12-14 05:54</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sabela Ojea \n</p>\n<pre>\n \n</pre>\n<p>\n  Outlook <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> said it would trim its workforce by 23% with the goal of extending its cash runway as long as possible and move forward with the commercial launch of Lytenava in the European Union and the U.K. \n</p>\n<p>\n  The biopharmaceutical company on Friday said that the layoffs follow an internal strategic review and would lead to annual savings of about $1.4 million. The company had cash and cash equivalents of $32 million as of June 30, down from $47.2 million as of March 31. \n</p>\n<p>\n  Lytenava is the subject of a centralized Marketing Authorization granted by the European Commission in the European Union and Marketing Authorization granted by the Medicines and Healthcare products Regulatory Agency in the U.K. for the treatment of wet age-related macular degeneration. \n</p>\n<p>\n  Wet AMD happens when abnormal blood vessels grow in the back of the eye and damage the macula. \n</p>\n<p>\n  The company continues to believe in the potential of Lytenava and is dedicated to advancing its regulatory and commercial efforts, Interim Chief Executive Lawrence Kenyon said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sabela Ojea at sabela.ojea@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 13, 2024 16:54 ET (21:54 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2491158649","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2491158649","pubTimestamp":1734126840,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Outlook Therapeutics said it would trim its workforce by 23% with the goal of extending its cash runway as long as possible and move forward with the commercial launch of Lytenava in the European Union and the U.K.The biopharmaceutical company on Friday said that the layoffs follow an internal strategic review and would lead to annual savings of about $1.4 million. The company had cash and cash equivalents of $32 million as of June 30, down from $47.2 million as of March 31.Lytenava is the subject of a centralized Marketing Authorization granted by the European Commission in the European Union and Marketing Authorization granted by the Medicines and Healthcare products Regulatory Agency in the U.K. for the treatment of wet age-related macular degeneration.Wet AMD happens when abnormal blood vessels grow in the back of the eye and damage the macula.The company continues to believe in the potential of Lytenava and is dedicated to advancing its regulatory and commercial efforts, Interim C","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","OTLK":"Outlook Therapeutics, Inc.","LENZ":"Therapeutics"},"translate_title":"Outlook Therapeutics将裁员23%以推动Lytenava的商业上市","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OTLK":0.9,"LENZ":1},"content_text":"By Sabela Ojea \n\n\n \n\n\n  Outlook Therapeutics said it would trim its workforce by 23% with the goal of extending its cash runway as long as possible and move forward with the commercial launch of Lytenava in the European Union and the U.K. \n\n\n  The biopharmaceutical company on Friday said that the layoffs follow an internal strategic review and would lead to annual savings of about $1.4 million. The company had cash and cash equivalents of $32 million as of June 30, down from $47.2 million as of March 31. \n\n\n  Lytenava is the subject of a centralized Marketing Authorization granted by the European Commission in the European Union and Marketing Authorization granted by the Medicines and Healthcare products Regulatory Agency in the U.K. for the treatment of wet age-related macular degeneration. \n\n\n  Wet AMD happens when abnormal blood vessels grow in the back of the eye and damage the macula. \n\n\n  The company continues to believe in the potential of Lytenava and is dedicated to advancing its regulatory and commercial efforts, Interim Chief Executive Lawrence Kenyon said. \n\n\n \n\n\n  Write to Sabela Ojea at sabela.ojea@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 13, 2024 16:54 ET (21:54 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}